Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating income | -$6.98M | -$15.3M | -$23.3M | -$33.3M | -$27.2M |
| Net income | -$13.8M | -$26.8M | -$20.3M | -$4.79M | -$26.3M |
| EPS (diluted) | — | -$1.73 | -$1.30 | -$43.68 | -$62.19 |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | -$7.75M | -$12.5M | -$23.7M | -$24.1M | -$28.2M |
| Capital expenditures | — | — | — | $457K | — |
| Free cash flow | — | — | — | -$24.6M | — |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Cash & equivalents | $57.3M | $41.0M | $21.3M | $862K | $10.5M |
| Total assets | $58.0M | $42.6M | $27.2M | $5.87M | $21.6M |
| Shareholders' equity | $27.7M | $10.3M | -$3.78M | -$2.68M | $17.3M |
| Retained earnings | -$29.1M | -$60.3M | -$80.7M | -$85.4M | -$112M |
| Shares (wtd avg diluted) | 4.52M | 15.5M | 15.6M | 110K | 423K |
Every figure is extracted from BriaCell Therapeutics Corp.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.